NASDAQ:ACAD ACADIA Pharmaceuticals - ACAD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding ACADIA Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $19.83 -0.08 (-0.40%) (As of 02/3/2023 09:03 PM ET) Add Compare Share Share Today's Range$19.53▼$20.1150-Day Range$14.49▼$19.9152-Week Range$12.24▼$28.06Volume1.23 million shsAverage Volume1.25 million shsMarket Capitalization$3.21 billionP/E RatioN/ADividend YieldN/APrice Target$20.56 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media ACADIA Pharmaceuticals MarketRank™ ForecastAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside3.7% Upside$20.56 Price TargetShort InterestBearish5.04% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.65Based on 10 Articles This WeekInsider TradingSelling Shares$342,038 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.31) to ($0.97) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.59 out of 5 starsMedical Sector854th out of 1,025 stocksPharmaceutical Preparations Industry418th out of 498 stocks 1.3 Analyst's Opinion Consensus RatingACADIA Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 11 buy ratings, 5 hold ratings, and 2 sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.56, ACADIA Pharmaceuticals has a forecasted upside of 3.7% from its current price of $19.83.Amount of Analyst CoverageACADIA Pharmaceuticals has only been the subject of 4 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted5.04% of the float of ACADIA Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverACADIA Pharmaceuticals has a short interest ratio ("days to cover") of 6.5.Change versus previous monthShort interest in ACADIA Pharmaceuticals has recently decreased by 4.53%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldACADIA Pharmaceuticals does not currently pay a dividend.Dividend GrowthACADIA Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ACAD. Previous Next 3.1 News and Social Media Coverage News SentimentACADIA Pharmaceuticals has a news sentiment score of 0.65. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 10 news articles for ACADIA Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest21 people have searched for ACAD on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added ACADIA Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ACADIA Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $342,038.00 in company stock.Percentage Held by Insiders28.40% of the stock of ACADIA Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.79% of the stock of ACADIA Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for ACADIA Pharmaceuticals are expected to grow in the coming year, from ($1.31) to ($0.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ACADIA Pharmaceuticals is -14.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ACADIA Pharmaceuticals is -14.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioACADIA Pharmaceuticals has a P/B Ratio of 5.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About ACADIA Pharmaceuticals (NASDAQ:ACAD) StockACADIA Pharmaceuticals, Inc. operates as a biopharmaceutical company. It focuses on the development and commercialization of medicines to address unmet medical needs in central nervous system, or CNS, disorders. The firm's products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.Read More Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Stock News HeadlinesFebruary 5, 2023 | americanbankingnews.comAnalysts Set ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Price Target at $20.56February 2, 2023 | americanbankingnews.comCitigroup Increases ACADIA Pharmaceuticals (NASDAQ:ACAD) Price Target to $19.00February 6, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 31, 2023 | markets.businessinsider.comAnalyst Expectations for ACADIA Pharmaceuticals's FutureJanuary 27, 2023 | americanbankingnews.comSVB Leerink Brokers Lower Earnings Estimates for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)January 20, 2023 | marketwatch.comPsychedelic Drugs Market Research report forecast 2023 To 2028, Latest Industry News, Top Company Analysis, Research MethodologyJanuary 16, 2023 | seekingalpha.comAcadia Pharmaceuticals: What's Ahead In 2023January 13, 2023 | thestreet.comAcadia Pharmaceuticals (ACAD) Stock Climbs on Drug Application for Parkinson's TreatmentFebruary 6, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 10, 2023 | marketwatch.comPsychedelic Medicine Market Size, Sales, CAGR And Competition Data from 2023 To 2028 with Top Countries DataJanuary 6, 2023 | reuters.comU.S. FDA approves Eisai, Biogen's Alzheimer's drugJanuary 3, 2023 | finance.yahoo.comInvestors in ACADIA Pharmaceuticals (NASDAQ:ACAD) from three years ago are still down 62%, even after 4.1% gain this past weekDecember 31, 2022 | reuters.comExclusive: Drugmakers to raise prices on at least 350 drugs in U.S. in JanuaryDecember 29, 2022 | cnbc.comCiti names its top biotech stock picks for 2023 — and gives one 73% upsideDecember 23, 2022 | reuters.comEisai, Biogen's new Alzheimer's drug should be priced below Aduhelm - reportDecember 23, 2022 | reuters.comU.S. FDA approves Roche's lymphoma therapyDecember 22, 2022 | reuters.comMerck's COVID pill does not cut hospitalisation, death rates in many vaccinated adults - studyDecember 22, 2022 | reuters.comU.S. FDA approves Gilead's long-acting HIV drug SunlencaDecember 21, 2022 | reuters.comU.S. FDA approves Roche's COVID-19 antibodyDecember 21, 2022 | reuters.comBioNTech doses first patient in herpes vaccine candidate clinical trialDecember 19, 2022 | marketwatch.comOral Dissolvable Films Market [ New Report ] 2023 to 2028 with Key Trends & New Business Opportunities by State and RegionDecember 19, 2022 | reuters.comMadrigal drug meets main goals in much-awaited NASH trialDecember 15, 2022 | msn.comUS Parkinson's disease incidence far higher than earlier estimates -studyNovember 15, 2022 | markets.businessinsider.comRBC Capital Keeps Their Buy Rating on Spruce Biosciences (SPRB)November 15, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Azenta (AZTA) and Syros Pharmaceuticals (SYRS)November 8, 2022 | finance.yahoo.comAcadia Pharmaceuticals to Participate at Upcoming Investor ConferencesNovember 4, 2022 | seekingalpha.comAcadia Pharmaceuticals: I Remain Cautiously Bullish After Q3 UpdatesSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ACAD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ACADIA Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address ACAD Company Calendar Last Earnings11/08/2021Today2/06/2023Next Earnings (Estimated)2/27/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ACAD CUSIPN/A CIK1070494 Webwww.acadia-pharm.com Phone(858) 558-2871Fax858-558-2872Employees514Year FoundedN/APrice Target and Rating Average Stock Price Forecast$20.56 High Stock Price Forecast$35.00 Low Stock Price Forecast$10.00 Forecasted Upside/Downside+3.7%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage18 Analysts Profitability EPS (Most Recent Fiscal Year)($1.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-167,870,000.00 Net Margins-42.49% Pretax Margin-42.12% Return on Equity-47.09% Return on Assets-34.23% Debt Debt-to-Equity RatioN/A Current Ratio4.47 Quick Ratio4.42 Sales & Book Value Annual Sales$484.14 million Price / Sales6.63 Cash FlowN/A Price / Cash FlowN/A Book Value$3.36 per share Price / Book5.90Miscellaneous Outstanding Shares161,930,000Free Float115,943,000Market Cap$3.21 billion OptionableOptionable Beta0.64 Key ExecutivesStephen R. DavisChief Executive Officer & DirectorBrendan P. TeehanChief Operating Officer, EVP & Head-CommercialMark C. SchneyerChief Financial Officer & Executive Vice PresidentBob MischlerSenior VP-Strategy & Technology OperationsPonni SubbiahChief Medical Officer & Senior Vice PresidentKey CompetitorsMirati TherapeuticsNASDAQ:MRTXHUTCHMEDNASDAQ:HCMAbCellera BiologicsNASDAQ:ABCLUltragenyx PharmaceuticalNASDAQ:RAREInsmedNASDAQ:INSMView All CompetitorsInsiders & InstitutionsEmerald Advisers LLCSold 7,480 shares on 2/3/2023Ownership: 0.816%Emerald Mutual Fund Advisers TrustBought 16,011 shares on 2/3/2023Ownership: 0.648%Empire Life Investments Inc.Sold 2,011 shares on 2/2/2023Ownership: 0.109%ProShare Advisors LLCBought 1,993 shares on 2/2/2023Ownership: 0.018%SG Americas Securities LLCSold 9,891 shares on 2/2/2023Ownership: 0.009%View All Insider TransactionsView All Institutional Transactions ACAD Stock - Frequently Asked Questions Should I buy or sell ACADIA Pharmaceuticals stock right now? 18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 2 sell ratings, 5 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ACAD shares. View ACAD analyst ratings or view top-rated stocks. What is ACADIA Pharmaceuticals' stock price forecast for 2023? 18 brokers have issued twelve-month price objectives for ACADIA Pharmaceuticals' shares. Their ACAD share price forecasts range from $10.00 to $35.00. On average, they anticipate the company's share price to reach $20.56 in the next year. This suggests a possible upside of 3.7% from the stock's current price. View analysts price targets for ACAD or view top-rated stocks among Wall Street analysts. How have ACAD shares performed in 2023? ACADIA Pharmaceuticals' stock was trading at $15.92 at the start of the year. Since then, ACAD shares have increased by 24.6% and is now trading at $19.83. View the best growth stocks for 2023 here. When is ACADIA Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023. View our ACAD earnings forecast. How were ACADIA Pharmaceuticals' earnings last quarter? ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) announced its earnings results on Monday, November, 8th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping analysts' consensus estimates of ($0.26) by $0.17. The biopharmaceutical company had revenue of $131.61 million for the quarter, compared to analysts' expectations of $127.77 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 47.09% and a negative net margin of 42.49%. The company's quarterly revenue was up 9.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.54) EPS. What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings? ACADIA Pharmaceuticals issued an update on its FY 2022 earnings guidance on Wednesday, November, 9th. The company provided EPS guidance of for the period. The company issued revenue guidance of $510.00 million-$520.00 million, compared to the consensus revenue estimate of $530.69 million. What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO? 8 employees have rated ACADIA Pharmaceuticals Chief Executive Officer Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among the company's employees. What other stocks do shareholders of ACADIA Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL). What is ACADIA Pharmaceuticals' stock symbol? ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD." Who are ACADIA Pharmaceuticals' major shareholders? ACADIA Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Emerald Advisers LLC (0.82%), Emerald Mutual Fund Advisers Trust (0.65%), Rice Hall James & Associates LLC (0.59%), Hennion & Walsh Asset Management Inc. (0.13%), Empire Life Investments Inc. (0.11%) and State of New Jersey Common Pension Fund D (0.10%). Insiders that own company stock include Austin D Kim, Austin D Kim, Brendan Teehan, Bros Advisors Lp Baker, Elena Ridloff, James Kihara, James M Daly, Laura Brege, Mark C Schneyer, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis. View institutional ownership trends. How do I buy shares of ACADIA Pharmaceuticals? Shares of ACAD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is ACADIA Pharmaceuticals' stock price today? One share of ACAD stock can currently be purchased for approximately $19.83. How much money does ACADIA Pharmaceuticals make? ACADIA Pharmaceuticals (NASDAQ:ACAD) has a market capitalization of $3.21 billion and generates $484.14 million in revenue each year. The biopharmaceutical company earns $-167,870,000.00 in net income (profit) each year or ($1.35) on an earnings per share basis. How many employees does ACADIA Pharmaceuticals have? The company employs 514 workers across the globe. How can I contact ACADIA Pharmaceuticals? ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The official website for the company is www.acadia-pharm.com. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at ir@acadia-pharm.com, or via fax at 858-558-2872. This page (NASDAQ:ACAD) was last updated on 2/6/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.